Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in developing adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinsons disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.
BCLI's NurOwn technology, an autologous adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells into specialized neuron-supporting cells. It also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center.
Brainstorm Cell Therapy was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. BCLI was founded in 2000 and is based in New York, New York.
December 18, 2024
RegMed Investors (RMi) Closing Bell: Jerome speaks with 25 basis point reduction and tanks the markets
December 17, 2024
RegMed Investors (RMi) Closing Bell: from the bottom of the stats, hits and balls keep sector on the board
December 3, 2024
RegMed Investors (RMi) Closing Bell: as compared to Monday, a wipeout
December 3, 2024
RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results
December 2, 2024
RegMed Investors (RMi) Closing Bell: tick, tock, kicks the upside
November 26, 2024
RegMed Investors (RMi) Closing Bell: a tug-of-war to a positive sector close after volatility reversals
November 20, 2024
RegMed Investors (RMi) Closing Bell: sector equities keep getting cheaper
November 15, 2024
RegMed Investors (RMi) Closing Bell: another wipe-out of value
November 8, 2024
RegMed Investors (RMi) Closing Bell: more slippage as sentiment dips
November 7, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector slippage
35 companies, 1 interpreter!
Insight, foresight and recommendation
Brainstorm Cell Therapeutics (BCLI) – January '18 openaed at $3.65, dropping in February to $3.45 and continuing to drop to $3.10 on 2/12 and $3.19 on 2/16. Even with their on-going trial, I have a problem with theor corporate transparency ... tey revolve on news and the pricing falls back ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.